2nd Edition of International Cancer & Immuno-Oncology Conference
March 19-21, 2026 | Singapore
Retinoblastoma Chemotherapies
Retinoblastoma, a rare childhood eye cancer, presents unique challenges in chemotherapy due to its location and age of onset. Chemotherapy regimens for retinoblastoma typically involve a combination of drugs to target the rapidly dividing cancer cells. Topotecan and carboplatin are commonly used in systemic chemotherapy, often administered intravenously. These drugs work by interfering with DNA replication and cell division, thereby halting the growth of cancerous cells. Additionally, intra-arterial chemotherapy directly delivers high doses of chemotherapy drugs to the eye through the ophthalmic artery, minimizing systemic side effects. Emerging therapies such as targeted molecular agents hold promise for more effective and less toxic treatments. As research advances, personalized approaches tailored to individual patients' genetic profiles may further enhance treatment outcomes in retinoblastoma.
Rajvir Dahiya
University of California San Francisco, United States
Atif A Ahmed
University of Washington-Seattle Children’s Hospital, United States
Anyou Wang
DIFIBER LLC, United States
Paulo Cesar De Morais
Catholic University of Brasilia, Brazil
Allen Chen
Olympic Medical Center, United States
Shilpa S Dhar
UT MD Anderson Cancer Center, United States
Ritu Khanna
University of Manchester, United KingdomSubmit your abstract Today
Title : A novel blood-based mRNA genomics technology for cancer diagnosis and treatment
Rajvir Dahiya, University of California San Francisco, United States
Title : tRNA-derived fragment 3′tRF-AlaAGC modulates cell chemoresistance and M2 macrophage polarization via binding to TRADD in breast cancer
Feng Yan, The Affiliated Cancer Hospital of Nanjing Medical University, China
Title : Integrating single-cell and spatial transcriptomics to uncover and elucidate GP73-mediated pro-angiogenic regulatory networks in hepatocellular carcinoma
Jiazhou Ye, Guangxi Medical University Cancer Hospital, China
Title : Unveiling the synergism of radiofrequency therapy and graphene nanocomposite in tumor cell viability assay
Paulo Cesar De Morais, Catholic University of Brasilia, Brazil
Title : Analysis of the dynamic evolution and influencing factors of nutritional risk in breast cancer patients during treatment
Jingwen Yan, Sun Yat-sen University, China
Title : Integrative multi-omics reveals metabolic–stemness coupling and novel therapeutic targets in osteosarcoma chemoresistance
Jinyan Feng, Tianjin Medical University Cancer Institute and Hospital, China